| HOME >> MEDICINE >> TECHNOLOGY |
Figure 3.10: Pharmaceutical price controls in major European markets 61
Figure 3.11: Pharmaceutical reimbursement systems in major European markets 62
Figure 3.12: Italian categorization for innovative new therapies 69
Figure 3.13: Future scenarios for pharmaceutical pricing and reimbursement in the major European markets 84
Figure 4.14: The Japanese National Health Insurance system, FY2008 92
Figure 4.15: Average NHI price cuts, 1998-2008 95
Figure 4.16: Future scenarios for pharmaceutical pricing and reimbursement in Japan 99
Figure 4.17: Real GDP growth in BRIC and major markets, 2008 103
Figure 5.18: International price differentials for leading drugs, 2008 110
Figure 5.19: Market share for new products launched in last five years, 2007 112
Figure 5.20: Delays in European market access, 2007 114
Figure 5.21: External reference pricing in Europe, 2009 116
Figure 5.22: Parallel imports as a share of pharmacy sales in Europe, 2007 118
Figure 6.23: Price demand and response curves 128
Figure 6.24: Market share and revenue impact of reimbursement and formulary status 130
Figure 6.25: Budget impact modeling 135
List of Tables
Table 1.1: Trends in healthcare spend as a proportion of GDP, 1990-2007 20
Table 1.2: Number of NME and BLA approvals by the FDA, 1999-2008 24
Table 1.3: R&D expenditure by PhRMA members, 1999-2008 26
Table 4.4: NHI price premium classifications for new drugs 93
Table 6.5: Pricing across the drug development and marketing lifecycle 137
To order this report:
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |